Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system

Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS

(2019) Huan-huan Ji et al.   CLINICAL DRUG INVESTIGATION

Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®

(2019) Carla Carnovale et al.   Expert Opinion On Drug Safety

Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance-pharmacodynamic study

(2018) Spyridon Siafis et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions

(2018) Gian Paolo Fadini et al.   Diabetes Therapy

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions

(2018) Gian Paolo Fadini et al.   Diabetes Therapy

Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems

(2017) E. Raschi et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Evaluation of the Expression Profile of Extrapyramidal Symptoms Due to Antipsychotics by Data Mining of Japanese Adverse Drug Event Report (JADER) Database

(2017) Eiji Kose et al.   YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications

(2016) Ruwen Böhm et al.   PLoS One

Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area

(2014) Birgitta Grundmark et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

DPP-4 inhibitors: pharmacological differences and their clinical implications

(2014) Antonio Ceriello et al.   Expert Opinion On Drug Safety

DPP-4 inhibitors: focus on safety

(2014) Sri Harsha Tella et al.   Expert Opinion On Drug Safety

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Combination with Metformin

(2013) Andrea D. Fass et al.   ADVANCES IN THERAPY

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations

(2012) Toshiyuki Sakaeda et al.   International Journal of Medical Sciences

pROC: an open-source package for R and S+ to analyze and compare ROC curves

(2011) Xavier Robin et al.   BMC BIOINFORMATICS

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System

(2011) Toshiyuki Sakaeda et al.   PLoS One

Disproportionality methods for pharmacovigilance in longitudinal observational databases

(2011) Ivan Zorych et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Efficacy and safety of incretin-based therapies: Clinical trial data

(2009) John White   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Quantitative signal detection using spontaneous ADR reporting

(2009) A. Bate et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

(2009) Roger Yazbeck et al.   TRENDS IN PHARMACOLOGICAL SCIENCES